Skip to Content
You are currently on the new version of our website. Access the old version .
VirusesViruses
  • Review
  • Open Access

13 September 2022

13 Pages

Antiretroviral Drug Discovery Targeting the HIV-1 Nef Virulence Factor

,
,
,
,
,
,
,
,
…
1
Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA
2
Fox Chase Chemical Diversity Center, Inc., Pennsylvania Biotechnology Center, Doylestown, PA 18902, USA
*
Author to whom correspondence should be addressed.
This article belongs to the Special Issue Viral Accessory Proteins

Abstract

While antiretroviral drugs have transformed the lives of HIV-infected individuals, chronic treatment is required to prevent rebound from viral reservoir cells. People living with HIV also are at higher risk for cardiovascular and neurocognitive complications, as well as cancer. Finding a cure for HIV-1 infection is therefore an essential goal of current AIDS research. This review is focused on the discovery of pharmacological inhibitors of the HIV-1 Nef accessory protein. Nef is well known to enhance HIV-1 infectivity and replication, and to promote immune escape of HIV-infected cells by preventing cell surface MHC-I display of HIV-1 antigens. Recent progress shows that Nef inhibitors not only suppress HIV-1 replication, but also restore sufficient MHC-I to the surface of infected cells to trigger a cytotoxic T lymphocyte response. Combining Nef inhibitors with latency reversal agents and therapeutic vaccines may provide a path to clearance of viral reservoirs.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.